Global Moderate Psoriasis Market

Global Moderate Psoriasis Market Size Insights Forecasts to 2035

• The Global Moderate Psoriasis Market Size Was valued at USD 12.4 Billion in 2024
• The Global Moderate Psoriasis Market Size is Expected to Grow at a CAGR of around 5.13% from 2025 to 2035
• The Worldwide Moderate Psoriasis Market Size is Expected to Reach USD 21.5 Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Moderate Psoriasis Market Size Was Worth Around USD 2.4 Billion In 2024 And Is Predicted To Grow To Around USD 21.5 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 5.13% From 2025 To 2035. Future opportunities in the global moderate psoriasis market will arise from multiple factors which include the expansion of biologic drugs and the integration of digital therapeutic solutions and the development of individualized treatment pathways and the increasing availability of healthcare services and government-sponsored reimbursement programs and the ongoing research and development funding which creates new patient-centered innovative solutions.

 

Market Overview

Moderate psoriasis is a long-lasting skin disorder which causes red scaly patches to develop on more than half of a person s body. The global moderate psoriasis market refers to the industry focused on developing, manufacturing, and distributing treatments for managing this condition. Additionally, the moderate psoriasis treatment market currently shows multiple opportunities for expansion which result from technological advancements and shifts in how consumers behave. Pharmaceutical companies can achieve substantial market gains through their development of biologics and targeted therapies which require them to allocate funds toward research and development. Patients who look for safer and more effective treatment options currently prefer these treatment methods because they offer both precise results and high effectiveness. Furthermore, the development of telemedicine technology creates a major chance to improve how patients participate in their medical treatment process. Digital technology usage in healthcare enables patients to receive medical consultations and monitor their treatment progress from their own homes. This trend helps people who live in distant locations and those who have difficulty moving because it helps them stick to their treatment plans while improving their overall health results.

 

Report Coverage

This research report categorizes the moderate psoriasis market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the moderate psoriasis market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the moderate psoriasis market. 

 

Driving Factors

The worldwide moderate psoriasis market experience growth because of three main factors which include increased psoriasis cases and heightened public knowledge of the condition and its early symptoms and the rising need for effective treatment solutions. The treatment results show improvement through the introduction of new biologic drugs which target immune pathways and the development of oral small-molecule medications and advanced topical treatment solutions. The market growth receives additional support from ongoing research and development together with precision medicine and digital diagnostic technologies.

 

Restraining Factors

The market for moderate psoriasis treatments which shows positive growth faces multiple challenges which threaten its expansion. The high costs associated treatment especially for biologic therapies create a major barrier because many patients find these treatments to be excessively expensive. The current situation restricts access to vital medical treatments which primarily affects developing countries that have unstable healthcare funding systems.

 

Market Segmentation

The moderate psoriasis market share is classified into product type and application.

 

• The topical treatments segment dominated the market in 2024, approximately 45% and is projected to grow at a substantial CAGR during the forecast period.

Based on the product type, the moderate psoriasis market is divided into topical treatments, systemic treatments, and phototherapy. Among these, the topical treatments segment dominated the market in 2024, approximately 45% and is projected to grow at a substantial CAGR during the forecast period. The therapy serves as a primary treatment option for patients who have mild to moderate medical conditions. The medical solutions provide simple access and affordable pricing while their use results in reduced negative health impacts. The market segment continues to expand because of ongoing product development in corticosteroids and vitamin D analogs and combination creams which doctors prefer to use.

• The hospitals segment accounted for the largest share in 2024, approximately 48% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the moderate psoriasis market is divided into hospitals, home care, and outpatient surgery centers. Among these, the hospitals segment accounted for the largest share in 2024, approximately 48% and is anticipated to grow at a significant CAGR during the forecast period. Hospitals deliver multiple services through their specialized dermatologist staff members who work with advanced diagnostic tools and deliver systemic therapies and biologic medications. The hospital system delivers two services through its operational phototherapy department which runs under staff supervision and its complete medical treatment program for patients who require moderate care. The combination of rising hospital attendance and enhanced healthcare facilities together with improved insurance reimbursement systems leads to substantial growth within this market segment.

 

Regional Segment Analysis of the Moderate Psoriasis Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the moderate psoriasis market over the predicted timeframe.

North America is anticipated to hold the largest share of the moderate psoriasis market over the predicted timeframe. The region had about 42% of global market share during the year 2024. The regional market expansion receives support from two factors which are increasing use of biologic treatments and existing reimbursement systems and growing research activities in dermatology.

 

Asia-Pacific is expected to grow at a rapid CAGR in the moderate psoriasis market during the forecast period. The region accounted for approximately 25% of the worldwide market share during the year 2024. The market development is driven by three factors which include rising healthcare investments, increasing pharmaceutical development activities, and the presence of a substantial patient base.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the moderate psoriasis market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• AbbVie Inc.
• Johnson & Johnson
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Pfizer Inc.
• UCB S.A.
• Bristol-Myers Squibb
• Sun Pharmaceutical
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

 

• In August 2025, researchers had reported that advances in immune-targeting therapies and a deeper understanding of skin immune cells had suggested a potential long-term cure for psoriasis might have been achievable within the next decade, offering hope for patients with chronic inflammatory skin disease

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the moderate psoriasis market based on the below-mentioned segments: 

 

Global Moderate Psoriasis Market, By Product Type

• Topical Treatments
• Systemic Treatments
• Phototherapy

 

Global Moderate Psoriasis Market, By Application

• Hospitals
• Home Care
• Outpatient Surgery Centers

 

Global Moderate Psoriasis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is driving the growth of the Global Moderate Psoriasis Market?

A: The market growth is driven by rising cases of Psoriasis, increasing awareness, demand for effective therapies, and innovations such as biologic drugs, targeted treatments, digital diagnostics, and continuous research and development activities.

 

2. Which product type dominated the moderate psoriasis market in 2024?

A: The topical treatments segment dominated the moderate psoriasis market in 2024 with about 45% share due to its first-line use, affordability, easy availability, and ongoing innovations in corticosteroids and vitamin D analog formulations.

 

3. Which application segment held the largest share in 2024?

A: Hospitals held the largest share of the moderate psoriasis market in 2024, around 48%, because they provide specialized dermatology care, advanced diagnostics, biologic therapies, supervised phototherapy, and comprehensive treatment services.

 

4. Which region dominates the global moderate psoriasis market?

A: North America dominates the global moderate psoriasis market with about 42% share in 2024, supported by strong healthcare infrastructure, widespread biologic therapy adoption, favorable reimbursement policies, and active dermatology research.

 

5. Which region is expected to grow the fastest in the market?

A: Asia-Pacific is expected to grow at the fastest CAGR due to rising healthcare investments, expanding pharmaceutical development, increasing awareness of psoriasis treatments, and a large patient population.